Inflammatory bowel disease

If oxalate in certain plant foods can irritate inflamed intestines or be less well absorbed in IBD, eating large amounts could worsen symptoms for some patients. Awareness can help people track triggers rather than...

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from International Journal of Drug Delivery...

For people with Crohn’s disease, this study suggests that biologic drugs reduce inflammation in both proximal and distal small bowel to a similar degree, as measured by capsule endoscopy.

Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Inflammatory bowel disease, and Infliximab. The original article is from Journal of Medical Case Reports.

Abdominal tuberculosis can closely mimic Crohn’s disease and abdominal cancers, so recognizing radiological and microbiological approaches that improve diagnosis helps avoid misdiagnosis and unnecessary surgery,...

Cure8 found this source from crohnscolitisfoundation.org, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Diet and lifestyle. Open the original article for the full details.

Postoperative pain control choices after ileocecectomy could affect Crohn's flare risk and opioid exposure. A pediatric center-level analysis found no association between ketorolac and flares and suggested reduced opioid...

Curcumin is a common dietary compound that reaches the colon and may interact with gut bacteria and host immune and barrier pathways implicated in IBD. Understanding these interactions could inform dietary approaches or...

Microbiome patterns in this study were linked to inflammation (fecal calprotectin) and higher chance of needing treatment escalation. If validated, enterotype stratification could help predict disease course or tailor...

For people with UC who do not respond to tacrolimus, adding infliximab may induce remission and reduce the short-term need for colectomy. The findings point to a potential rescue strategy and an option to transition to...

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Strictureplasty. The original article is from Surgical Endoscopy.

Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease and Community and awareness. The original article is from BMC Health Services Research.

This project explores whether common environmental chemicals (PFAS) might change biological processes years before IBD appears, which could help explain some cases of Crohn’s disease and ulcerative colitis and point...

Patients and clinicians choosing a next biologic after prior biologic failure may find evidence here that effectiveness is broadly similar between vedolizumab and ustekinumab overall, with potential differences depending...

The review links TCM-derived compounds to mechanisms (microbiota, metabolites, immunity) that are implicated in progression from chronic colitis to colorectal cancer, which is an important long-term risk for people with...

If validated, mucosal biomarkers like SPARC and SPP1 might help predict who will not respond to infliximab, potentially guiding treatment choices and avoiding ineffective therapy for some people with UC.

People with Crohn’s disease may see emerging interest in traditional Chinese medicine as a multi-target approach that could complement standard treatments and affect immune pathways, the gut barrier, and the microbiome.

Vitamin D deficiency is common in people with IBD and can affect bone health and possibly immune function.

People with IBD and RA often try dietary changes to manage symptoms. This trial is testing two very low-carbohydrate approaches to see if they affect symptoms, quality of life, and inflammation, and whether they are...

The study describes real-world use of a treat-to-target approach in adults with Crohn's disease and ulcerative colitis, which may influence how clinicians monitor disease and adjust therapy in routine care.

Diet is a potentially modifiable factor that could affect symptoms, inflammation, and the gut microbiome in ulcerative colitis; this trial aims to test whether a modified Mediterranean diet added to standard therapy...

Preclinical research suggests acebrophylline might reduce inflammation and oxidative stress in an experimental mouse model of ulcerative colitis, which could be an early step toward new treatments that target multiple...

Bowel urgency is a common, distressing symptom in ulcerative colitis that matters for quality of life. This analysis indicates vedolizumab may reduce urgency and that early improvement is linked to better clinical and...

Preclinical work identifies a natural-product mixture that reduced inflammation, improved gut barrier markers, and changed the microbiome in a mouse model of ulcerative colitis. This could be an early step toward new...

Eating out can be challenging for people with Crohn's disease because fat content and daily symptom variability affect tolerance. Practical strategies from someone with long-term experience can help other patients...

The study suggests IBD patients can fall into two distinct gut-microbe/metabolite types that align with differences in disease severity and mental-health scores, which could help explain why patients with the same...

The study identifies a molecular epithelial program (GART-associated) linked to proliferation and purine metabolism in ulcerative colitis, which could inform future mechanistic research and biomarker development relevant...

The study identifies and functionally validates a new STXBP3 variant that likely causes VEOIBD with immunodeficiency, which can help explain disease in affected infants and inform genetic counseling and further research.

The study suggests a new microbiota–metabolite–immune pathway (palmitic acid → PI3K/AKT → NETs) that may drive colitis and that Forsythia polysaccharides can modify, which could point to future microbiota-targeted...

The paper describes a novel colon-targeted delivery system that improved local drug retention, reduced dosing frequency, and changed microbiota and metabolic markers in a mouse model of UC — developments that could...

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Microbiome, and Research and clinical trials. The original article is from Gut Pathogens.

The study tests combined neutralization of two pro-inflammatory cytokines plus IL‑10 in a mouse colitis model and reports reduced inflammation and restored macrophage cellular pathways, which may inform future IBD...

Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease and Procedures and surgery. The original article is from Updates in Surgery.

Crohn's is becoming more common among younger Americans and long-term uncontrolled inflammation raises colorectal cancer risk. Understanding possible lifestyle and medical factors can help patients and clinicians focus...

Understanding whether innate lymphoid cells retain ‘memory’ that drives psoriasis relapse could reveal biomarkers to monitor recurrence and suggest new therapeutic targets for patients with recurrent disease.

This project explores how CD74 in intestinal stem cells and Paneth cells helps control mucosal immune responses and epithelial repair — processes directly relevant to IBD pathogenesis and recovery.

People with IBD on biologic therapies may benefit from accurate drug-level testing to guide treatment decisions.

If shorter, non-contrast MRE protocols can reliably show Crohn’s activity and strictures, patients could have faster scans with less gadolinium exposure. But if ulceration or penetrating disease is suspected,...

People with IBD are at increased risk of bone loss; this study points to a microbiome-related pathway (A. muciniphila and an IDA metabolite) that might protect bone in an experimental colitis model, which could...

Localized hydrogel drug delivery aims to concentrate therapy at inflamed gut sites while reducing systemic side effects — a potentially useful approach for people with IBD who have inadequate response or intolerable...

An oral diabetes drug (empagliflozin) may reduce a toxic metabolite linked to neutropenia and inflammation in GSD Ib, and this case report suggests it helped an adult patient’s blood counts, infections risk, and...

The study explores a novel, non-invasive way to deliver an IL-23–blocking protein to the gut using engineered Lactococcus lactis, which could eventually offer an alternative to systemic biologics for controlling...

Patients with multiple biologic failures appear more likely to have inflammatory comorbidities (including IBD) and to experience worse dermatology-related quality of life despite similar early skin improvement. That...

The study describes a new nanozyme-based oral formulation that reduced NET formation and improved mucosal healing in a mouse model of ulcerative colitis, suggesting a novel preclinical approach to long‑term...

PSC co-occurring with celiac disease appears more common than expected and is associated with a high rate of liver complications (including cirrhosis) and frequent coexisting IBD—information that may affect monitoring...

People with IBD often hear about “treat-to-target” as a path to deeper healing.

Nanozyme-based therapeutics are an emerging experimental strategy that aim to reduce oxidative stress and modulate immune responses in the inflamed gut — mechanisms directly relevant to IBD pathophysiology.

Oxidative stress may be a key driver of inflammation in IBD and could point to new biomarkers or adjunctive treatments (dietary changes, antioxidant strategies, or targeted pathways like Nrf2 and ferroptosis) that...